Prof. Philippe Courtet
Université de Montpellier, Francia
| Ponencia | Tratamiento de la auto-violencia |
| Fechas | 9 Septiembre - 11 Septiembre, 2020 |
| Mesa redonda 6 | El Manejo de la Violencia y la Agresión |
BIOGRAFÍA
Philippe Courtet es profesor de psiquiatría en la Universidad de Montpellier y jefe del departamento de psiquiatría de urgencias e intentos de suicidio del Hospital Universitario de Montpellier (Francia). Dirige la Cátedra de excelencia en prevención del
suicidio de la Fundación Fundamental. Dirige el grupo de investigación "vulnerabilidad del comportamiento suicida" en el INSERM. Sus áreas de interés involucran la vulnerabilidad al comportamiento suicida en pacientes con trastornos del estado de
animo, centrándose en la genómica, las imágenes cerebrales y la investigación del dolor social. Ahora está implementando proyectos utilizando herramientas de salud conectada para la evaluación y manejo de pacientes con riesgo suicida.
El Profesor Courtet es presidente del grupo de trabajo "suicidio" de la Federación Mundial de Sociedades de Psiquiatría Biológica, ex presidente de la Asociación Francesa de Psiquiatría Biológica y Neuropsicofarmacología. Es miembro de la Asociación Europea de Psiquiatría (EPA) y del Colegio Europeo de Neuropsicofarmacología (ECNP).
Ha publicado 299 artículos en revistas revisadas por pares, numerosos capítulos de libro. Ha sido editor de tres libros sobre el comportamiento suicida.
El Profesor Courtet es presidente del grupo de trabajo "suicidio" de la Federación Mundial de Sociedades de Psiquiatría Biológica, ex presidente de la Asociación Francesa de Psiquiatría Biológica y Neuropsicofarmacología. Es miembro de la Asociación Europea de Psiquiatría (EPA) y del Colegio Europeo de Neuropsicofarmacología (ECNP).
Ha publicado 299 artículos en revistas revisadas por pares, numerosos capítulos de libro. Ha sido editor de tres libros sobre el comportamiento suicida.
RESUMEN
Throughout the world, approximately 800,000 people die by suicide every year. This explains that suicidal behaviour (SB) still represents a major public health issue. However, despite the multiplication of the therapeutic strategies for psychiatric disorders during the last decades, the incidence of SB has not substantially decreased. A new era is coming with evidence-based strategies, both pharmacological and psychosocial, which should lead to change the way we deal with suicidal patients. Then, this presentation will focus on recent findings that should be implemented in our health care systems.
Up to 2016, a systematic review published in the Lancet Psychiatry reported that only few interventions provided good evidence for suicide prevention. Health care strategies were based on the treatment of depression and chain of care.
During the last 5 years, have appeared new strategies based on a paradigm shift, suggesting that we are entering in a new era for suicide prevention. Importantly, most efforts to develop interventions have moved away from the view that treating the underlying psychiatric disorder would prevent SB, to a perspective that suicide- specific treatments are more than necessary.
This new conceptualization allowed to carry out studies investigating directly the effect of some interventions in depressed patients at high risk of SB. These studies provide strong evidence favouring the implementation of short-term interventions in these patients, as soon as their visit in Emergency rooms. Pharmacological interventions suggest the relevance of drugs acting on the glutamatergic and opioid systems. Psychosocial interventions are particularly based on safety plan, phone contacts and close follow-up.
Then, we have now more evidence-based strategies than ever to prevent suicide, which should lead clinicians and stakeholders to organise care specifically for suicidal patients.
Up to 2016, a systematic review published in the Lancet Psychiatry reported that only few interventions provided good evidence for suicide prevention. Health care strategies were based on the treatment of depression and chain of care.
During the last 5 years, have appeared new strategies based on a paradigm shift, suggesting that we are entering in a new era for suicide prevention. Importantly, most efforts to develop interventions have moved away from the view that treating the underlying psychiatric disorder would prevent SB, to a perspective that suicide- specific treatments are more than necessary.
This new conceptualization allowed to carry out studies investigating directly the effect of some interventions in depressed patients at high risk of SB. These studies provide strong evidence favouring the implementation of short-term interventions in these patients, as soon as their visit in Emergency rooms. Pharmacological interventions suggest the relevance of drugs acting on the glutamatergic and opioid systems. Psychosocial interventions are particularly based on safety plan, phone contacts and close follow-up.
Then, we have now more evidence-based strategies than ever to prevent suicide, which should lead clinicians and stakeholders to organise care specifically for suicidal patients.